Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Drug Details

General Information of the Drug (ID: DR0366)
Name
Belinostat
Synonyms
Belinostat; 414864-00-9; PXD101; Belinostat (PXD101); 866323-14-0; Beleodaq; PXD-101; (E)-N-hydroxy-3-(3-(N-phenylsulfamoyl)phenyl)acrylamide; NSC726630; N-HYDROXY-3-(3-PHENYLSULFAMOYLPHENYL)ACRYLAMIDE; PXD 101; UNII-F4H96P17NZ; PX-105684; N-HYDROXY-3-[3-[(PHENYLAMINO)SULFONYL]PHENYL]-2-PROPENAMIDE; 2-Propenamide, N-hydroxy-3-[3-[(phenylamino)sulfonyl]phenyl]-, (2E)-; F4H96P17NZ; (2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide; CHEBI:61076; PX 105684; (2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]acrylamide; (E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide.; E-Belinostat; Belinostat [USAN:INN]; N-hydroxy-3-(3-(phenylsulfamoyl)phenyl)prop-2-enamide; PX105684; 2-Propenamide, N-hydroxy-3-(3-((phenylamino)sulfonyl)phenyl)-, (2E)-; Belinostat Ph3; Beleodaq (TN); PubChem22405; Belinostat - PXD101; Belinostat (USAN/INN); Belinostat (PXD101); N-Hydroxy-3-(3-phenylsulphamoylphenyl)acrylamide; cc-489; MLS006011091; CHEMBL408513; GTPL7496; BDBM25150; CHEBI:94531; AMY1792; DTXSID60194378; EX-A180; QCR-181; (E)-3-[3-(phenylsulfamoyl)phenyl]prop-2-enehydroxamic acid; BCPP000351; AOB87787; BCP01741; ZINC3818726; Belinostat,PXD101, PX105684; Belinostat/PXD101,PX105684/; ABP000140; MFCD08064035; NSC758774; s1085; AKOS025401741; BCP9000386; CCG-208758; DB05015; LS41098; NSC-726630; NSC-758774; SB16466; NCGC00263155-02; NCGC00263155-05; AC-25046; AS-17068; SMR004702879; AB0007889; SW219445-1; EC-000.2286; A25012; D08870; W-5363; J-523584; Q4882925; BRD-K17743125-001-01-9; N-Hydroxy-3-[(phenylamino)sulfonyl]-trans-cinnamamide; (E)-N-Hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide; 5OG
    Click to Show/Hide
Molecular Type
Small molecule
Disease Solid tumour/cancer [ICD-11: 2A00-2F9Z] Phase 2 [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C15H14N2O4S
PubChem CID
6918638
Canonical SMILES
C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO
InChI
1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+
InChIKey
NCNRHFGMJRPRSK-MDZDMXLPSA-N
CAS Number
CAS 866323-14-0
ChEBI ID
CHEBI:61076
TTD Drug ID
D0XT6W
DrugBank ID
DB05015
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Vincristine      Catharanthus roseus     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation
Up-regulation Expression BCL2L11  Molecule Info 
Pathway MAP
Down-regulation Expression MCL1  Molecule Info 
Pathway MAP
                    In-vitro Model SU-DHL-4 CVCL_0539 B-cell lymphoma Homo sapiens
DB CVCL_1168 B-cell lymphoma Homo sapiens
OCI-Ly19 CVCL_1878 B-cell lymphoma Homo sapiens
SU-DHL-8 CVCL_2207 B-cell lymphoma Homo sapiens
GM18564 CVCL_P179 Healthy Homo sapiens
                    Experimental
                    Result(s)
Vincristine sensitizes DLBCL cells to the cytotoxic effects of belinostat.
Target and Pathway
Target(s) Histone deacetylase (HDAC)  Molecule Info  [3]
References
Reference 1 A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015 Mar;168(6):811-9.
Reference 2 Belinostat and vincristine demonstrate mutually synergistic cytotoxicity associated with mitotic arrest and inhibition of polyploidy in a preclinical model of aggressive diffuse large B cell lymphoma. Cancer Biol Ther. 2016 Dec;17(12):1240-1252.
Reference 3 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China